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Abstract Non-steroidal anti-inflammatory drugs (NSAIDs)
currently attract large interest. Next to pain relief, NSAIDs
have important anti-thrombotic and anti-oncogenic effects.
NSAIDs exert their action by inhibition of cyclooxygenase, the
enzyme responsible for the production of prostanoids. Prostanoid
signal transduction is still poorly understood, but it has become
clear that these inflammatory lipids influence cellular physiology
at three different levels : (1) activation of a 7U transmembrane
receptor coupled to heterotrimeric G proteins, (2) the inhibition
of inflammation by activating corticosteroid-like receptors, (3)
participation in receptor protein tyrosine kinase signal transduc-
tion. In this review prostanoid signalling at these three different
levels will be reviewed and the relevance in (patho)physiological
processes will be evaluated.
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1. Introduction
Non-steroidal anti-in£ammatory drugs (NSAIDs), such as
aspirin, have been used with great therapeutic success for over
a century. The mechanism of action of these drugs has long
remained a mystery. In 1982, however, the Nobel Prize in
Physiology or Medicine was awarded to Sune Bergstrom,
Bengt Samuelson and John Vane for their work on prosta-
glandins and biochemically related substances (now desig-
nated the prostanoid type of eicosanoids [1]), and the demon-
stration that NSAIDs act by interfering with the synthesis of
these in£ammatory lipids. Since then it has become clear that
prostanoids act in a broad range of biological and (patho)-
physiological processes, such as in£ammation, thrombosis,
and cancer. An important role for prostanoid signalling is
further supported by the evolutionary conservation of this
signalling: also plants and yeasts are capable of prostaglandin
synthesis (e.g. [2,3]), and the prostanoid-generating system
probably dates from before 3.0 billion years ago [4]. As will
become clear from this review, however, prostanoid signalling
and its relation to these pathophysiological e¡ects are still
poorly understood, but seem to be mediated via e¡ects on
both plasma membrane receptors and intracellular receptors,
as well as by action downstream of receptor activation.
2. Synthesis and structure of prostanoids
Prostanoids were ¢rst discovered in the 1930s, when
Von Euler showed that semen compounds are able to lower
blood pressure in experimental animals [1]. Synthesis of pros-
tanoids is rate limited by the release of the precursor lipid
arachidonic acid from plasma membrane phospholipids. Ei-
ther phospholipase A2 or the combined action of phospholip-
ase C, a diglyceride lipase and a monoglyceride lipase, pro-
duces arachidonic acid. Upon its release, arachidonic acid is
converted by cyclooxygenase (COX) to PGG2 and subse-
quently peroxidised to PGH2 by the same enzyme, which
acts as a precursor for further prostanoid synthesis by speci¢c
prostaglandin synthetases which are often expressed in a cell
type-speci¢c fashion. All prostanoids are composed of oxy-
genated, 20 carbon fatty acids, which contain a cyclic ring,
a C-13CC-14 trans double bond and a hydroxyl group at C-
15. Prostanoids can be divided into prostaglandins (PG),
which contain a cyclopentane ring, and thromboxanes (TX),
which contain a cyclohexane ring. The ¢rst group include the
prostaglandins of the D, E, F, and I series, the latter indicat-
ing the locations of the oxygen group(s) in the cyclopentane
ring. Likewise, thromboxanes are subdivided into TXA and
TXB. Commonly, these abbreviations are followed by an in-
dex (for instance PGE2), which indicates the number of dou-
ble bonds present in the side chains attached to the cyclo-
pentane ring. Five primary prostanoids are distinguished:
PGD2, PGE2, PGI2, PGF2K and TXA2 (Fig. 1, [5]), the exact
metabolites synthesised being dependent on the tissue type
and stimulus. For instance, TXs, PGD2, PGI2, PGF2K are
major metabolites in platelets, mast cells, endothelial cells,
and kidney glomerulus cells respectively. In contrast, PGE2
is synthesised by a broad range of cell types (for references,
e.g. [5]).
3. Cyclooxygenase I and II
As stated above, prostanoid synthesis critically depends on
the action of cyclooxygenase (Fig. 2). Two isoforms of this
enzyme exist (COX-1 and COX-2) which share 60% amino
acid homology. The most striking di¡erence between COX-1
and -2 is the ultrastructural localisation. Whereas COX-2 acts
at the nuclear envelope [6], COX-1 functions predominantly in
the endoplasmic reticulum and close to the plasma membrane.
This di¡erential localisation of the COX-isoforms is the con-
sequence of di¡erences occurring in the signal peptides and
membrane binding domains near the N- and C-terminal ends
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[7^9]. The functional importance, if any, of this di¡erential
localisation is unclear.
COX-1 is constitutively expressed in many mammalian tis-
sues [10], albeit at di¡erent levels. The level of COX-1 expres-
sion remains considerably constant and is only increased after
stimulation of the cells with growth factors, cytokines or tu-
mour promoting agents [11^14]. From this, it was concluded
that COX-1 is essential for common though primary func-
tions, such as the aggregation of platelets and regulation of
renal blood £ow [15,16]. Although COX-1 was not thought to
be a major target of NSAIDs during in£ammation, COX-1-
negative mice displayed reduced experimental in£ammation
and gastric ulceration [17]. In addition, these mice exhibit
strongly diminished fertility, although the physiological basis
for this e¡ect remains unexplained.
COX-2 is not detected in most tissues, but levels of expres-
sion are induced rapidly upon stimulation of cells with various
substances including growth factors [18], cytokines [19], and
endotoxins [20]. Although it is generally assumed that COX-2
is the important NSAID target during in£ammation, gene
disruption of COX-2 in mice induces nephropathy but does
not alter in£ammatory responses [21]. Together with the sup-
port for a role of COX-1 in in£ammation from knockout
experiments, the exact functioning of both enzymes in this
process is probably more subtle than previously thought.
COX-2 overexpression in rat intestinal epithelial cells re-
sulted in increased adhesion to the extracellular matrix, dimin-
ished E-cadherin expression, and enhanced levels of Bcl2 [22].
In addition, these cells became more resistant to butyrate-in-
duced apoptosis. Interestingly, knockout of COX-2 decreased
the size and number of polyps in mice su¡ering from intestinal
polyposis and COX-2 overexpression is associated with tu-
morigenesis [23]. Together, these observations indicate that
COX-2 inhibition may be important in chemoprevention of
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Fig. 1. Structure of the primary prostanoids and their precursors. A: The subsequent products of PGH synthase (COX), PGG2 and PGH2 are
depicted. B: The structure of the ¢ve primary prostanoids PGD2, PGE2, PGF2K, PGI2 and TXA2.
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cancer by NSAIDs [24]. A recent study by DuBois et al. [25],
however, demonstrated that both COX-1 and COX-2 inhib-
ition are important targets for the chemoprevention of cancer
by NSAIDs through inhibition of neo-angiogenesis. Whereas
COX-1 was essential for the formation of the endothelial tube,
COX-2 was essential for the production of angiogenic factors,
again demonstrating that NSAID actions in pathophysiology
are not easily attributed to e¡ects on a single COX isoform.
4. Prostanoid receptors
In general, prostanoid receptors belong to either the super-
family of G protein-coupled rhodopsin type of receptors or to
the superfamily of nuclear steroid/thyroid hormone receptors.
Within the family of G protein-coupled receptors, the prosta-
noid receptors constitute a subfamily, with remarkably low
overall homology ranging from 24 to 44%. These prostanoid
receptors are named after the ligand they bind: PD which
binds PGD, TP which binds TX, PI which binds PGI, TF
which binds PGF and PE which binds PGE. Of the PE re-
ceptor four subtypes exist named EP1, EP2, EP3 and EP4
[26]. These receptors display considerable cell type-speci¢c ex-
pression. The TP receptor, for instance, is mainly found in
platelets, EP1 in ¢broblasts, EP2 and EP4 in smooth muscle
cells, FP in kidney cells and astrocytes. Therefore, apart from
localised production of the di¡erent prostanoids, their action
is further restricted by localised receptor expression. This lo-
calised action may account for the highly speci¢c e¡ect seen in
the EP4 knockout mouse: only the perinatal closure of the
ductus arteriosus is a¡ected [27].
In general, these plasma membrane-localised prostanoid re-
ceptors can be grouped into three categories, depending on
the heterotrimeric G proteins to which they couple and thus
to the cellular response these receptors elicit via their C-ter-
minal regions. The ¢rst category consists of IP, EP2, EP4 and
DP ([28^30] and references therein, [31]) which lead to the
activation of adenylate cyclase via Gs. The second category
encompasses the TP, EP1 and FP type of prostanoid receptors
[32^35] and are coupled to the mobilisation of Ca2 via Gq
and phosphatidylinositol turnover. In addition, TP also acti-
vates Gi2, G12, G13 and an unidenti¢ed G protein of 85 kDa
[36^38], functions may be related to the action of TP in hae-
mostasis. It is currently not known to which G protein EP1 is
coupled, but it is generally implicated in calcium channel gat-
ing.
The EP3 type receptor is an exceptional case ([39] and
references therein): in general it activates Gi [40,41] but due
to its alternative splicing forms, di¡ering only in the carboxy-
terminal tails, it is capable of inducing a range of e¡ects.
Murine EP3K, L and Q, for instance, are all activators of Gi,
but with di¡erent e⁄ciencies [42]. Bovine EP3A activates Gi,
whereas EP3B activates Gs. Bovine EP3D stimulates all three
main G proteins, whereas EP3C couples to G0 next to Gs [43].
Coupling of bovine EP3C to G0 results in its inhibition, en-
hancing its a⁄nity for GTP dissociation factor [44]. Action of
the di¡erent EP3 receptor subtypes therefore displays consid-
erable species speci¢city.
In addition to these plasma membrane receptors, also the
peroxisome proliferator-activated receptor Q (PPARQ) [45], a
member of the nuclear hormone receptor superfamily, has
been identi¢ed as a prostanoid receptor. This interaction is
not as speci¢c as is prostanoid binding, to the transmembrane
receptor, the Kd for prostanoid binding to this intracellular
receptor (2 WM) being much larger than that of transmem-
brane receptors (varying over a range of 1.2^40 nM). PPARQ
has been shown to bind several ligands including 15-deoxy-
v12ÿ14prostaglandin J2 (15-d-PGJ2) which is a metabolite of
PGD2, and interestingly, also NSAIDs. Upon activation,
PPARQ heterodimerises with the retinoic acid receptor
(RXR) [46] and binds to speci¢c DNA sequences (peroxisome
proliferator responsive elements), activating target genes. Like
PPARK, an intracellular leukotriene receptor, PPARQ can
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Fig. 2. Schematic representation of the prostanoid synthesis pathway.
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bind and inactivate NF-UB, thus knocking out in£ammatory
responses [47]. In agreement, stimulation of PPARQ with 15-d-
PGJ2 results in reduced production of in£ammatory products
[47,48]. Since inhibition of in£ammation only occurs in the
presence of high intracellular concentrations of 15-d-PGJ2,
it is plausible that this inhibition acts as a feedback mecha-
nism on prostaglandin in£ammation. Furthermore, as PPARQ
is also activated by NSAIDs these compounds not only inter-
fere with in£ammation by inhibition of COX, but also di-
rectly, via stimulation of this class of receptors. A role in
NF-UB regulation has recently also been described for some
but not all NSAIDs acting through the inhibition of the NF-
UB activator IKKL [49], suggesting a threefold anti-in£amma-
tory role for NSAIDs by regulating both inhibition of COX
and NF-UB as well as activation of PPARQ.
Interestingly, very recently new e¡ects mediated by PPARQ
have been described. It has been suggested that PPARQ may
be important for atherogenesis (e.g. [50]). Furthermore, they
have also been associated with colon cancer [51,52]. Since high
intracellular concentrations of 15-d-PGJ2 have been shown to
serve as PPARQ ligands, this correlates with the e¡ects seen
after excessive prostaglandin production. In contrast, activa-
tion of PPARQ has also been shown to result in reversal of
malignant changes in colon cancer [53], again demonstrating
the complicity of prostanoid signalling.
5. Prostanoids as second messengers
A number of observations indicate that prostanoids also act
downstream of receptors, as second messengers. We have
shown that growth factor-dependent actin reorganisation re-
quires PG synthesis [54]. Furthermore, in smooth muscle cells,
cPLA2 activity and PGE2 were required for a PDGF-induced
rise in cAMP and PKA activation [55]. HGF-induced [56] and
EGF-induced [57] DNA synthesis was also demonstrated to
be dependent on COX activity. NSAID e¡ects on cancer may
therefore relate to inhibition of receptor tyrosine kinase-in-
duced mitogenesis. Also, Muthalif et al. [58] presented evi-
dence for a prostanoid-dependent activation of MAPK by
angiotensin in rabbit aortic smooth muscle cells. Whether
these e¡ects are mediated via autocrine stimulation of prosta-
noid receptors or represent a genuine action of these lipids as
second messengers is unknown. Nevertheless it is clear that
prostanoids act in cellular physiology at multiple levels, and
that the actions of NSAIDs in pathophysiology may only be
fully explained if the exact functioning of prostanoids at these
di¡erent levels is understood.
References
[1] Oates, J.A. (1982) Science 218, 765^768.
[2] Baker, M.E. (1995) Proc. Soc. Exp. Biol. Med. 208, 131^138.
[3] Botha, A. and Kock, J.L. (1993) Anthonie van Leeuwenhoek 63,
111^123.
[4] Peppelenbosch, M.P., Tertoolen, L.G.J., De Laat, S.W. and Ziv-
kovic, D. (1995) Exp. Cell Res. 218, 183^188.
[5] Smith, W.L., Marnett, L.J. and DeWitt L, D. (1991) Pharmacol.
Ther. 49, 153^179.
[6] Morita, I., Schindler, M., Regier, M.K., Otto, J.K., Hori, T.,
DeWitt, D. and Smith, W.L. (1995) J. Biol. Chem. 270, 10902^
10908.
[7] Kraemer, S.A., Meade, E.A. and DeWitt, D.L. (1992) Arch.
Biochem. Biophys. 293, 391^400.
[8] Kujubu, D.A. and Herschman, H.R. (1992) J. Biol. Chem. 267,
7991^7994.
[9] Smith, W.L. (1992) Am. J. Physiol. 263, F181^F191.
[10] O’Neill, G.P. and Ford-Hutchinson, A.W. (1993) FEBS Lett.
330, 156^160.
[11] DeWitt, D.L. (1991) Biochim. Biophys. Acta 1083, 121^134.
[12] Smith, C.J., Morrow, J.D., Roberts, L.J. and Marnett, L.J.
(1993) Biochem. Biophys. Res. Commun. 192, 787^793.
[13] Samet, J.M., Fasano, M.B., Fonteh, A.N. and Chilton, F.H.
(1995) J. Biol. Chem. 270, 8044^8049.
[14] Murakami, M., Matsumoto, R., Austen, K.F. and Arm, J.P.
(1994) J. Biol. Chem. 269, 22269^22275.
[15] Funk, C.D., Funk, L.B., Kennedy, M.E., Pong, A.S. and Fitz-
gerald, G.A. (1991) FASEB J. 5, 2304^2312.
[16] Merlie, J.P., Fagan, D., Mudd, J. and Needleman, P. (1988)
J. Biol. Chem. 263, 3550^3553.
[17] Langenbach, R., Morham, S.G., Tiano, H.F., Loftin, C.D., Gha-
nayem, I.B., Chulada, P.C., Mahler, J.F., Lee, C.A., Goulding,
E.H., Kluckman, K.D., Kim, H.S. and Smithies, O. (1995) Cell
83, 483^492.
[18] Lee, S.H., Soyoola, F., Chanmugam, P., Hart, S., Sun, W.,
Zhong, H., Liou, S., Simmons, D. and Hwang, D. (1992)
J. Biol. Chem. 267, 25934^25938.
[19] Maier, J.A., Hla, T. and Maciag, T. (1990) J. Biol. Chem. 265,
10805^10808.
[20] Xie, W., Robertson, D.L. and Simmons, D.L. (1992) Drug Dev.
Res. 25, 249^265.
[21] Morham, S.G., Langenbach, R., Loftin, C.D., Tiano, H.F., Vou-
loumanos, N., Jennette, J.C., Mahler, J.F., Kluckman, K.D.,
Ledford, A., Lee, C.A. and Smithies, O. (1995) Cell 83, 473^482.
[22] Tsujii, M. and Dubois, R.N. (1995) Cell 83, 493^501.
[23] DuBois, R.N., Radhika, A., Reddy, B.S. and Enting, A.J. (1996)
Gastroenterology 110, 1259^1262.
[24] Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Han-
cock, B., Kwong, E., Trzaskos, J.M., Evans, J.F. and Taketo,
M.M. (1996) Cell 87, 803^809.
[25] DuBois, R.N., Gupta, R., Brockman, J., Reddy, B.S., Krakow,
S.L. and Lazar, M.A. (1998) Carcinogenesis 19, 49^53.
[26] Coleman, R.A., Kennedy, I., Humphrey, P.P.A., Bunce, K. and
Lumley, P. (1990) Comp. Med. Chem., Membranes and Recep-
tors, Vol. 3, pp. 643^714, Pergamon Press, Oxford.
[27] Nguyen, M.T., Camenisch, T.M., Snouwaert, J.N., Hicks, E.,
Co¡man, T.M., Anderson, P.A.W., Malouf, M.N. and Koller,
B.H. (1997) Nature 390, 78^81.
[28] Adie, E.J., Mullaney, I., McKenzie, F.R. and Milligan, G. (1992)
Biochem. J. 285, 529^536.
[29] Reimer, R., Heim, H.K., Muallem, R., Odes, H.S. and Sewing,
K.F. (1992) Prostaglandins 44, 485^493.
[30] Ichikawa, A., Sugimoto, Y. and Negishi, M. (1996) J. Lipid
Mediators Cell Signall. 14, 83^87.
[31] Trist, D.G., Collins, B.A., Wood, J., Kelly, M.G. and Robertson,
A.D. (1989) Br. J. Pharmacol. 96, 301^306.
[32] Mayeux, P.R., Mais, D.E., Carr, C. and Halushka, P.V. (1989)
J. Pharmacol. Exp. Ther. 250, 923^927.
[33] Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Ne-
gishi, M., Ito, S., Naruyima, S. and Ichikawa, A. (1993) J. Biol.
Chem. 268, 20175^20178.
[34] Funk, C., Furchi, L., Fitzgerald, G., Grygorczyk, R., Rochette,
C., Bayne, M.A., Abramovitz, M., Adam, M. and Metters, K.M.
(1993) J. Biol. Chem. 268, 16767^26772.
[35] Watanabe, T., Yatomi, Y., Sunaga, S., Miki, I., Ishii, A., Nakao,
A., Higashihara, M., Seyama, Y., Ogura, M., Saito, H., Kuro-
kawa, K. and Shimizu, T. (1994) Blood 78, 2328^2336.
[36] Ushikubi, F., Nakamura, K. and Naruyima, S. (1994) Mol. Phar-
macol. 46, 808^816.
[37] O¡ermanns, S., Laugwitz, K.L., Spicher, K. and Schultz, G.
(1994) Proc. Natl. Acad. Sci. USA 91, 504^508.
[38] Knezevic, I., Borg, C. and Le Breton, G.C. (1993) J. Biol. Chem.
268, 26011^26017.
[39] Ichikawa, A., Sugimoto, Y. and Negishi, M. (1996) J. Lipid
Mediators Cell Signall. 14, 83^87.
[40] Nishigaki, N., Negishi, M., Sugimoto, Y., Namba, T., Naruyima,
S. and Ichikawa, A. (1993) Biochem. Pharmacol. 46, 863^869.
[41] Schwaner, I., O¡ermans, S., Spicher, K., Seifert, R. and Schultz,
G. (1995) Biophys. Biochim. Acta 1265, 8^14.
FEBS 21577 19-2-99
H.H. Versteeg et al./FEBS Letters 445 (1999) 1^54
[42] Tanabe, Y., Masu, M., Ishii, T., Shigemoto, R. and Nakanishi,
S. (1992) Neuron 8, 169^179.
[43] Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F.,
Kakizuka, A., Ito, S., Ichikawa, A. and Naruyima, S. (1993)
Nature 365, 166^170.
[44] Negishi, M., Namba, T., Sugimoto, Y., Irie, A., Katada, T.,
Naruyima, S. and Ichikawa, A. (1993) J. Biol. Chem. 268,
26067^26070.
[45] Tontonoz, P., Hu, E., Divine, E., Beale, E.G. and Spiegelman,
B.M. (1994) Mol. Cell. Biol. 15, 351^357.
[46] Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A. and
Evans, R.M. (1992) Nature 358, 771^774.
[47] Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. and Glass, C.K.
(1998) Nature 391, 79^82.
[48] Jiang, C., Ting, A.T. and Seed, B. (1998) Nature 391, 82^86.
[49] Yin, M.J., Yamamoto, Y. and Gaynor, R.B. (1998) Nature 396,
77^80.
[50] Tontonoz, P., Nagy, L., Alvarez, J.G.A., Thomazy, V.A. and
Evans, R.M. (1998) Cell 93, 241^252.
[51] Saez, E., Tontonoz, P., Nelson, M.C., Alvarez, J.G.A., U, T.M.,
Baird, S.M., Thomazy, V.A. and Evans, R.M. (1998) Nature
Med. 4, 1058^1061.
[52] Lefebvre, A., Chen, I., Desreumaux, P., Najib, J., Fruchart, J.,
Geboes, K., Briggs, M., Heyman, R. and Auwerx, J. (1998) Na-
ture Med. 4, 1053^1058.
[53] Saraf, P., Mueller, E., Jones, D., King, F.J., DeAngelo, D.J.,
Partridge, J.B., Holden, S.A., Chen, L.B., Singer, S., Fletcher,
C. and Spiegelman, B.M. (1998) Nature Med. 4, 1046^1052.
[54] Peppelenbosch, M.P., Tertoolen, L.G., Hage, W.J. and De Laat,
S.W. (1993) Cell 74, 565^575.
[55] Graves, L.M., Bornfeldt, K.E., Sidhu, J.S., Argast, G.M.,
Raines, E.W., Ross, R., Leslie, C.C. and Krebs, E.G. (1996)
J. Biol. Chem. 271, 505^511.
[56] Adachi, T., Nakashima, S., Shigetoyo, S., Nakamura, T. and
Nozawa, Y. (1996) Hepatology 23, 1244^1253.
[57] Handler, J.A., Danilowics, R.M. and Eling, T.E. (1990) J. Biol.
Chem. 265, 3669^3673.
[58] Muthalif, M.M., Benter, I.F., Uddin, M.R., Harper, J.L. and
Malik, K.U. (1998) J. Pharmacol. Exp. Ther. 284, 388^398.
FEBS 21577 19-2-99
H.H. Versteeg et al./FEBS Letters 445 (1999) 1^5 5
